Related Experiment Video

Updated: Jun 20, 2026

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

Thrombocytopenia and hemostatic disorders in chronic graft versus host disease

D Pulanic1, J N Lozier, S Z Pavletic

  • 1Graft-versus-Host and Autoimmunity Unit, Experimental Transplantation and Immunology Branch, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.

Bone Marrow Transplantation
|August 18, 2009
PubMed

Insights

Chronic graft versus host disease (cGVHD) can cause low platelet counts, increasing complications and mortality. Understanding the multifactorial causes of these hemostatic disorders is crucial for improving patient outcomes.

Area of Science:

  • Hematology
  • Transplantation Medicine
  • Immunology

Background:

  • Chronic graft versus host disease (cGVHD) is a frequent complication after allogeneic stem cell transplantation.
  • Thrombocytopenia (low platelet count) in cGVHD patients is a strong predictor of poor survival.
  • The mechanisms linking thrombocytopenia to poor outcomes in cGVHD are not well understood.

Purpose of the Study:

  • To explore the correlation between thrombocytopenia and survival in cGVHD.
  • To elucidate the multifactorial etiology of hemostatic disorders in cGVHD.
  • To identify potential therapeutic strategies targeting hemostasis.

Main Methods:

  • Review of existing cGVHD studies correlating thrombocytopenia with survival outcomes.
  • Analysis of factors contributing to hemostatic disorders in cGVHD patients.
  • Discussion of potential therapeutic targets for future clinical trials.

Main Results:

  • Low platelet counts in cGVHD are linked to increased complications and treatment-related mortality.
  • Thrombocytopenia is generally not associated with higher relapse rates or engraftment failure.
  • Hemostatic disorders in cGVHD have a multifactorial origin, including tissue injury, cytokine release, and impaired thrombopoietin levels.

Conclusions:

  • Thrombocytopenia is a significant prognostic factor in cGVHD, impacting survival through increased complications.
  • Interventions aimed at stimulating platelet production or correcting hemostatic imbalances warrant investigation.
  • Future clinical trials should focus on agents that improve megakaryocytopoiesis and hemostasis to enhance outcomes for cGVHD patients.

More Related Videos

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR06:06

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR

Published on: May 23, 2019

Induction of Intestinal Graft-versus-host Disease and Its Mini-endoscopic Assessment in Live Mice09:50

Induction of Intestinal Graft-versus-host Disease and Its Mini-endoscopic Assessment in Live Mice

Published on: February 11, 2019

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview